Dogwood Therapeutics (DWTX) investor relations material

Executive summary

• Focused on developing therapies for pain and neuropathy associated with cancer, with Halneuron® in Phase 2b for chemotherapy-induced neuropathic pain (CINP) and SP16 entering Phase 1 for chemotherapy-induced peripheral neuropathy (CIPN), both advancing in clinical trials.

• Halneuron Phase 2b trial enrolled 164 patients, with top-line results expected in fall 2026.

• FDA accepted SP16 IND application for chemotherapy-induced pain and neuropathy; Phase 1b trial to begin mid-2026, fully funded by the National Cancer Institute.

• Entered a global licensing agreement for anti-viral candidates IMC-1 and IMC-2, with potential milestone payments up to $100 million.

• No product revenue to date; operations funded by equity and debt financings.

Financial highlights

• Net loss for Q1 2026 was $5.0 million, a significant improvement from $10.9 million or $12.2 million in Q1 2025.

• Operating expenses increased to $5.1 million from $4.4 million year-over-year, driven by higher R&D and G&A costs.

• R&D expenses for Q1 2026 were $2.7 million, up from $2.4 million year-over-year, mainly due to drug development and personnel costs.

• G&A expenses rose to $2.4 million, primarily from higher salaries and personnel costs.

• Cash and cash equivalents at March 31, 2026 were $13.2 million, providing operational runway into Q4 2026.

Outlook and guidance

• Cash on hand expected to fund operations into Q4 2026; additional financing required beyond that to continue clinical trials and operations.

• Top-line results from the Halneuron® Phase 2b CINP trial expected in fall 2026.

• SP16 Phase 1b trial for CIPN to commence mid-2026, funded by the National Cancer Institute.